問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

劉興璟Liu, HsingJin Eugene
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉興璟

List

22Cases

2023-06-01 - 2028-11-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-05-01 - 2034-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2017-01-15 - 2019-07-15

Phase II

Completed
A PHASE 2, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, CONTROLLED STUDY OF PEMETREXED MAINTENANCE WITH OR WITHOUT ADXS11-001 IMMUNOTHERAPY IN SUBJECTS WITH HUMAN PAPILLOMAVIRUS-POSITIVE, NON-SQUAMOUS, NONSMALL CELL LUNG CARCINOMA FOLLOWING FIRST-LINE INDUCTION CHEMOTHERAPY

  • Condition/Disease

    LUNG CARCINOMA

  • Test Drug

    ADXS11-001

Participate Sites
5Sites

Not yet recruiting1Sites

Study ended1Sites

2009-04-15 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-06-01 - 2022-12-31

Phase II

A PHASE 2, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, CONTROLLED STUDY OF PEMETREXED MAINTENANCE WITH OR WITHOUT ADXS11-001 IMMUNOTHERAPY IN SUBJECTS WITH HUMAN PAPILLOMAVIRUS-POSITIVE, NON-SQUAMOUS, NONSMALL CELL LUNG CARCINOMA FOLLOWING FIRST-LINE INDUCTION CHEMOTHERAPY

  • Condition/Disease

    LUNG CARCINOMA

  • Test Drug

    ADXS11-001

Participate Sites
9Sites

Terminated9Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2009-09-15 - 2010-06-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-10-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2010-05-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2015-06-02 - 2019-11-30

Phase II

A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 Positive Label.

  • Condition/Disease

    NSCLC

  • Test Drug

    Ficlatuzumab (AV-299),

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2016-01-31 - 2017-02-10

Phase I

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1)) will evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI4736 in adult patients with solid tumors. A dose exploration cohort will look at the safety profile of Q4W dosing of MEDI4736.

  • Condition/Disease

    NSCLC

  • Test Drug

    MEDI4736 & Tremelimumab

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB